Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: an international multicentre clinical trial

Filippo Murina, Ciprian Crişan, Marius Biriş, Daniela Sîrbu, View ORCID ProfileDionisio Franco Barattini, Luca Ivan Ardolino, Elena Casolati
doi: https://doi.org/10.1101/674705
Filippo Murina
Lower Genital Tract Disease Unit, Vittore Buzzi Hospital-University of Milan, Via Lodovico Castelvetro, 32 – 20154 Milano Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: filippo.murina@asst-fbf-sacco.it
Ciprian Crişan
Clinica Medicală Dr. Crişan Ciprian, Strada Salcâmilor 22, Timişoara 300425, România
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marius Biriş
Clinica Medicală Biriş Marius, Bd 16 Decembrie 1989 22-24, Timişoara, România
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Sîrbu
Clinica Medicală Dr. Sîrbu Daniela, Str. Sfinţii Apostoli Petru şi Pavel 15, Timişoara, 300269 România
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dionisio Franco Barattini
Opera CRO, a TIGERMED Group company, Strada Cozia 10, Timişoara 300209, România
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dionisio Franco Barattini
Luca Ivan Ardolino
Effik Italia, Via dei Lavoratori, 54 – 20092 Cinisello Balsamo Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Casolati
Private Practice of Obstetrics and Gynecology, Altamedica Milano, L. Ildefonso Schuster, 1 – 20122 Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Several risk factors have been identified but the etiology and pathogenesis of Bacterial vaginosis (BV) are still not completely understood, and the recurrence rate of BV remains high despite adequate chemotherapy treatment.

The primary objective of the study was to assess the effectiveness of a new vaginal medical device, which contains polycarbophil, 0.04 % lauryl glucoside, and glycerides (Polybactum® – Effik Italia), in reducing BV recurrence rate.

This was a multicenter, open label, not comparative study performed in Italy and Romania. Female subjects over 18-years-old affected by recurrent BV were included. The latest episode was diagnosed by Amsel criteria 6-9 days before the start of the study and treated with vaginal metronidazole (gel 0.75% mg for 5 days or ovules 500 mg for 7 days). The recurrence was defined by at least 2 episodes in the previous 12 months. Polybactum® vaginal ovules, day 1-4-7, were started within the 12th and the 24th hr after the end of metronidazole therapy and repeated monthly for 3 cycles.

The first 41 patients enrolled were evaluated for an interim analysis 6 months after the study started; 2 patients interrupted the trial, leaving 39 evaluable subjects. The recurrence rate was significantly reduced compared to previous published data (10.26% vs 40% p<0.001). In 35 patients without recurrence, the assessment of Lactobacillus vaginal flora performed by phase contrast microscopy evidenced a significant improvement form baseline (p=0.022) The Investigator global assessment of tolerability was excellent in 38 out of 39 cases.

IMPORTANCE Bacterial vaginosis (BV) is the most common vaginal disorder in women of childbearing age. In BV, Lactobacillus species, which are predominant in a healthy vaginal flora, are replaced by anaerobes, mainly Gardnerella vaginalis. BV is responsible for more than 60% of vulvovaginal infections and has been linked to serious, potentially life-threatening conditions, including: pelvic inflammatory disease, postoperative infections, acquisition and transmission of the human immunodeficiency virus, preterm birth, and several adverse pregnancy outcomes. Our research showed that 3 monthly cycles of Polybactum® ovules administered after one course of metronidazole vaginal therapy can reduce the rate of Bacterial vaginosis recurrence and improve the vaginal milieu, favouring the growth of vaginal lactobacillus species. Taken together our results confirm that Polibactum® is a safe and effective treatment to reduce BV recurrence rate after a first line therapy with metronidazole.

Footnotes

  • filippo.murina{at}asst-fbf-sacco.it, drcipriancrisan{at}gmail.com, marius308{at}yahoo.com, sirbudaniela47{at}yahoo.com, barattini{at}operacro.com, Luca.Ardolino{at}effikitalia.it, ecasolati{at}tin.it

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 21, 2019.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: an international multicentre clinical trial
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
Share
Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: an international multicentre clinical trial
Filippo Murina, Ciprian Crişan, Marius Biriş, Daniela Sîrbu, Dionisio Franco Barattini, Luca Ivan Ardolino, Elena Casolati
bioRxiv 674705; doi: https://doi.org/10.1101/674705
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: an international multicentre clinical trial
Filippo Murina, Ciprian Crişan, Marius Biriş, Daniela Sîrbu, Dionisio Franco Barattini, Luca Ivan Ardolino, Elena Casolati
bioRxiv 674705; doi: https://doi.org/10.1101/674705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Clinical Trials
Subject Areas
All Articles
  • Animal Behavior and Cognition (1519)
  • Biochemistry (2473)
  • Bioengineering (1727)
  • Bioinformatics (9648)
  • Biophysics (3884)
  • Cancer Biology (2961)
  • Cell Biology (4173)
  • Clinical Trials (135)
  • Developmental Biology (2620)
  • Ecology (4084)
  • Epidemiology (2031)
  • Evolutionary Biology (6868)
  • Genetics (5195)
  • Genomics (6482)
  • Immunology (2176)
  • Microbiology (6909)
  • Molecular Biology (2746)
  • Neuroscience (17197)
  • Paleontology (125)
  • Pathology (425)
  • Pharmacology and Toxicology (703)
  • Physiology (1050)
  • Plant Biology (2478)
  • Scientific Communication and Education (642)
  • Synthetic Biology (828)
  • Systems Biology (2680)
  • Zoology (429)